Evaluate the Reactogenicity & Immunogenicity of 1 or 2 Booster Administrations of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults Aged Between 19 & 61 Years.
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Adjuvants
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 04 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Nov 2008 Checked against CLinicalTrials.gov record.